RNS Number:6546L
Maelor PLC
29 May 2003


                                 Press Release


                                   MAELOR PLC



Maelor plc, the AIM listed specialist healthcare products company, today
announced the appointment of M S Jacovides as its exclusive distributor for
ContiSolTM, its range of catheter maintenance solutions, in Greece and Cyprus,
with options for the Balkan countries and Turkey.

ContiSol will be the first product to be launched by Maelor following the audit
of its Quality Management System and the company's certification to affix CE
marks to new products. ContiSol is essentially similar to Maelor's lead product
OptiFloTM, which is licensed to Bard Limited for certain other territories.

Jacovides is a fully integrated biopharmaceutical and medical devices company
founded in 1944. With annual sales of Euro39 million, Jacovides has an impressive
list of partner companies including Amgen, Biogen and Shire Pharmaceuticals. Its
medical devices business has grown at 25% per year for the last 5 years and it
is one of the leading companies in this sector of the Greek market.

Maelor CEO, Stephen Appelbee, said:

'We are delighted to welcome Jacovides as our first distribution partner for
ContiSol. Jacovides' strength in its markets will be an enormous asset to Maelor
in developing sales of ContiSol. We expect to launch this important new product
later this financial year, and while the Greek market is smaller than the UK, we
hope to replicate the success of OptiFlo with Contisol in Greece, Cyprus and
other markets.'


ContiSolTM is a trademark of Maelor Pharmaceuticals.

OptiFloTM is a trademark of Bard Limited


For further information:

Paul Williams, CFO                                       01978 810153

Ann-marie Wilkinson, Beattie Financial:                  020 7398 3300



Notes to Editors:

ContiSol is a range of solutions designed to prolong the life of indwelling
urological catheters and to prevent blockages. The range offers an appropriate
choice of agents for the management of catheter problems, such as blockages,
encrustation, and the formation of sediment, all of which may lead to infection.
The container has been designed to enable either medical staff or the patient,
through gentle agitation of the solution in the lumen of the catheter, to
achieve optimal dissolution and flushing. ContiSol is designed to reduce the
need for frequent catheter change.

END




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
CNTUWVBROARVUAR